OIS@AAO 2015

Aerie Pharmaceuticals

By Tom Salemi | November 24, 2015

Rhopressa is a Rho-kinase inhibitor that increases the outflow of the trabecular meshwork by relaxing it. It’s also a norepinephrine transport inhibitor that decreases the…

Read More

Ophthotech Corporation

By Tom Salemi | November 24, 2015

Fovista is an anti-platelet derived growth factor (PDGF) agent for wet age-related macular degeneration (AMD) combination therapy currently in phase 3 studies. Pending regulatory approval,…

Read More

Spark Therapeutics

By Tom Salemi | November 24, 2015

Spark was founded about 2 years ago with the vision of building a fully integrated gene therapy company with research and development, manufacturing, and commercial…

Read More

Second Sight Medical Products

By Tom Salemi | November 24, 2015

The Argus II transmits images wirelessly to a layer of 60 tiny electrodes on the retina inside the eye, to reverse vision lost as a…

Read More

Alimera

By Tom Salemi | November 24, 2015

Alimera Sciences is “dedicated to change the paradigm of how we think about and subsequently treat diabetic macular edema (DME),” Mr. Myers said. Iluvien is…

Read More

Digital Ophthalmology Sector Overview

By Tom Salemi | November 24, 2015

Participant: Michelle Snyder Michelle is currently the CMO at Welltok leading all corporate and product marketing efforts and is an investment and operational advisor to…

Read More

Ophthalmic Innovation 2015 – “A View from the AAO”

By Tom Salemi | November 24, 2015

Participant: David Parke, MD II Dr. Parke is CEO of the American Academy of Ophthalmology. Prior to assuming this role, Dr. Parke served as president…

Read More

Ophthalmic Innovation 2015 – “A View from the NEI”

By Tom Salemi | November 24, 2015

Participant: Paul A. Sieving, MD, PhD Dr. Sieving became Director of the National Eye Institute after serving as the Paul R. Lichter Professor of Ophthalmic…

Read More

Alcon – Google Innovation: Visions of Ophthalmology in 2020

By Tom Salemi | November 24, 2015

Participants: William J. Link, PhD Prior to Versant, Bill was a general partner at Brentwood Venture Capital. He founded, and served as chairman and CEO…

Read More

Thinking About Market Cycles & Growth in the Ophthalmology Sector

By Tom Salemi | November 24, 2015

A panel of Wall Street analysts offer their insights on the future performance of the public markets, including ophthalmology stocks at OIS@AAO in Las Vegas.…

Read More

Masters of the Universe

By Tom Salemi | November 24, 2015

Participants: Jim Mazzo James V. Mazzo is Global President for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and…

Read More
Implandata - Companies to Watch - 2015

Implandata

By Tom Salemi | November 23, 2015

Implandata Ophthalmic Products GmbH (IOP GmbH), located in Hanover/Germany, is destined to transform management of glaucoma patients via a unique solution for early detection of…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.